Bone Marrow Transplantation News

Older patients with myelodysplastic syndrome who underwent donor-matched allogeneic hematopoietic stem cell transplant had significantly improved survival outcomes compared with those who did not have a matched donor, study results showed.

Ruxolitinib conferred a higher overall response rate than best available therapy for certain patients with chronic graft-versus-host disease, according to results of an analysis presented at the virtual ASH Annual Meeting and Exposition.

Recombinant human granulocyte colony-stimulating factor combined with minimal-dose decitabine appeared to reduce relapse incidence after allogeneic transplant among patients with high-risk acute myeloid leukemia, study results showed.

Late effects of pediatric cancer treatment may not be readily apparent to primary care clinicians or specialists who follow childhood cancer survivors over the long term.

Early cytomegalovirus reactivation after allogeneic stem cell transplantation induced cytomegalovirus antigen-specific T cells that may better prevent future infection, according to results of a retrospective study.

ASH announced the election of four new members to its executive committee.

Children undergoing hematopoietic stem cell transplants for cancer had higher rates of transplant-related mortality if they lived in a poorer neighborhood, according to results of a study published in Blood.

Anthony S. Fauci, MD will be a keynote speaker during a special session at this year’s virtual ASH Annual Meeting and Exposition.

A phase 3 trial of omidubicel has shown the graft modality superior to standard umbilical cord blood for bone marrow transplantation in patients with hematologic malignancies, according to topline data released by the agent’s manufacturer.

The FDA issued a complete response letter to a biologics license application that seeks approval of remestemcel-L to treat certain children with graft-versus-host disease.